# The Synthesis and Biological Evaluation of 2-(1H-Indol-3-yl)quinazolin-4(3H)-One Derivatives
## 2 Results and Discussion
### In Vitro Biological Evaluation
#### 2.2.3 Cytotoxicity Activity
\begin{table}
\begin{tabular}{c c c c c c c c c} \hline \hline \multirow{2}{*}{**Compounds**} & \multicolumn{2}{c}{**MCF\({}^{\prime}\)**} & \multicolumn{2}{c}{**VA13**} & \multicolumn{2}{c}{**A549**} & \multicolumn{2}{c}{**HEK293T**} \\ \cline{2-9}  & **IC\({}_{\textbf{80}}\)** & **IC\({}_{\textbf{50 abs}}\)** & **IC\({}_{\textbf{50}}\)** & **IC\({}_{\textbf{50 abs}}\)** & **IC\({}_{\textbf{50}}\)** & **IC\({}_{\textbf{50 abs}}\)** & **IC\({}_{\textbf{50}}\)** & **IC\({}_{\textbf{50 abs}}\)** \\ \hline
**3b** & \(2.1\pm 0.4\) & \(27.1\pm 4.7\) & \(11.4\pm 1.2\) & \(29.4\pm 4.3\) & \(2.1\pm 0.3\) & \(3.6\pm 0.4\) & \(6.2\pm 0.7\) & \(8.3\pm 0.7\) \\
**3c** & \(4.1\pm 0.6\) & \(10.9\pm 1.1\) & \(3.7\pm 0.4\) & \(4.0\pm 0.2\) & \(3.7\pm 0.4\) & \(1.7\pm 0.2\) & \(1.8\pm 0.7\) & \(3.4\pm 0.6\) \\
**3d** & \(\mathrm{le}^{\mathrm{b}}\) & \(\mathrm{x}\times 100\) & \(47.0\pm 11.8\) & \(69.3\pm 3.1\) & \(43.0\pm 5.1\) & \(40.5\pm 2.7\) & \(5.5\pm 0.9\) & \(56.8\pm 7.9\) \\
**3e** & \(\mathrm{x}\times 100\) & \(\mathrm{x}\times 100\) & \(\mathrm{x}\times 100\) & \(-\) & \(8.0\pm 2.3\) & \(-\) & \(1\) & \(\mathrm{x}\times 100\) \\
**3f** & \(4.9\pm 0.7\) & \(7.1\pm 0.8\) & \(3.4\pm 0.4\) & \(3.8\pm 0.3\) & \(0.96\pm 0.18\) & \(1.3\pm 0.09\) & \(0.95\pm 0.28\) & \(1.9\pm 0.16\) \\
**3g** & \(0.57\pm 0.05\) & \(27.6\pm 7.4\) & \(0.84\pm 0.38\) & \(13.5\pm 3.6\) & \(0.75\pm 0.07\) & \(3.3\pm 0.6\) & \(0.73\pm 0.15\) & \(9.8\pm 2.5\) \\
**3i** & \(11.8\pm 0.7\) & \(10.9\pm 0.6\) & \(6.6\pm 0.5\) & \(7.1\pm 0.4\) & \(117.1\pm 1.2\) & \(9.0\pm 0.7\) & \(3.4\pm 0.2\) & \(4.1\pm 0.3\) \\
**3k** & \(5.9\pm 0.3\) & \(6.1\pm 0.3\) & \(7.9\pm 0.4\) & \(8.5\pm 0.3\) & \(6.5\pm 0.2\) & \(6.5\pm 0.2\) & \(3.4\pm 0.1\) & \(3.5\pm 0.1\) \\
**3o** & \(\mathrm{na. }^{c}\) & \(57.1\pm 6.2\) & \(-\) & \(67.8\pm 21.1\) & \(9.1\pm 1.2\) & \(38.1\pm 6.4\) & \(\mathrm{na. }\) & \(19.8\pm 3.4\) \\
**3q** & \(\mathrm{-20}\) & \(19.7\pm 2.5\) & \(16.5\pm 2.5\) & \(23.2\pm 2.9\) & \(6.1\pm 1.1\) & \(6.9\pm 0.6\) & \(8.2\pm 1.1\) & \(9.0\pm 0.7\) \\
**3r** & \(5.4\pm 2.2\) & \(\mathrm{x}\times 100\) & \(2.5\pm 0.7\) & \(60.1\pm 23.0\) & \(3.5\pm 0.3\) & \(27.6\pm 4.9\) & \(1.8\pm 0.4\) & \(48.9\pm 13.6\) \\
**3s** & \(13.6\pm 1.2\) & \(10.1\pm 1.0\) & \(13.5\pm 1.8\) & \(12.9\pm 0.8\) & \(9.4\pm 0.3\) & \(9.3\pm 0.3\) & \(12.4\pm 0.5\) & \(12.7\pm 0.4\) \\
**3t** & \(\mathrm{x}\times 33.3\) & \(\mathrm{x}\times 33.3\) & \(\mathrm{x}\times 33.3\) & \(\mathrm{x}\times 33.3\) & \(\mathrm{x}\times 33.3\) & \(\mathrm{x}\times 33.3\) & \(\mathrm{x}\times 33.3\) & \(\mathrm{x}\times 33.3\) \\
**3u** & \(0.30\pm 0.14\) (le) & \(\mathrm{x}\times 100\) & \(\mathrm{x}\times 100\) & \(\mathrm{x}\times 100\) & \(\mathrm{n.a. }\) & \(107.4\pm 27.7\) & \(\mathrm{n.a. }\) & \(66.8\pm 3.6\) \\
**3v** & \(\mathrm{n.a. }\) & \(93.0\pm 3.1\) & \(\mathrm{n.a. }\) & \(80.6\pm 3.9\) & \(\mathrm{n.a. }\) & \(57.0\pm 3.9\) & \(\mathrm{n.a. }\) & \(62.9\pm 2.8\) \\
**3w** & \(0.53\pm 0.44\) (le) & \(\mathrm{x}\times 100\) & \(\mathrm{x}\times 100\) & \(\mathrm{115.8}\pm 0.2\) & \(\mathrm{n.a. }\) & \(105.1\pm 15.8\) & \(\mathrm{n.a. }\) & \(104.8\pm 2.1\) \\
**3x** & \(\mathrm{le}\) & \(\mathrm{x}\times 100\) & \(\mathrm{le}\) & \(\mathrm{x}\times 100\) & \(\mathrm{le}\) & \(\mathrm{x}\times 100\) & \(\mathrm{le}\) & \(\mathrm{x}\times 100\) & \(\mathrm{x}\times 100\) \\
**3y** & \(\mathrm{x}\times 100\) & \(\mathrm{x}\times 100\) & \(\mathrm{x}\times 100\) & \(\mathrm{x}\timesFigure 3: In vitro cytotoxicity of the compounds **3b**, **3d–3g**, **k**, and **3r** to cells MCF7, A549, HEK293T, and VA13 via MTT assay.